Claims for Patent: 7,214,683

Summary for Patent: 7,214,683

Title:	Compositions of descarboethoxyloratadine
Abstract:	Methods are disclosed utilizing DCL, a metabolic derivative of loratadine, for the treatment of allergic rhinitis, and other disorders, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines.
Inventor(s):	Aberg; A. K. Gunnar (Westborough, MA), McCullough; John R. (Worcester, MA), Smith; Emil R. (Shrewsbury, MA)
Assignee:	Sepracor Inc. (Marlborough, MA)
Application Number:	09/039,260
Patent Claims:	1. A pharmaceutical composition which comprises 0.1 to 10 mg of descarboethoxyloratadine, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 2. The pharmaceutical composition of claim 1, which is adapted for oral administration. 3. The pharmaceutical composition of claim 1, which is solid. 4. The pharmaceutical composition of claim 3, which is in the form of capsule or tablet. 5. The pharmaceutical composition of claim 1, wherein the carrier is selected from the group consisting of microcrystalline cellulose, starch, silicon dioxide, magnesium stearate, lactose, and a combination thereof. 6. The pharmaceutical composition of claim 5, wherein the carrier comprises microcrystalline cellulose. 7. The pharmaceutical composition of claim 5, wherein the carrier comprises starch. 8. The pharmaceutical composition of claim 5, wherein the carrier comprises silicon dioxide. 9. The pharmaceutical composition of claim 5, wherein the carrier comprises magnesium stearate. 10. The pharmaceutical composition of claim 5, wherein the carrier comprises lactose. 11. A pharmaceutical composition comprising: a) 0.1 mg to 10 mg descarboethoxyloratadine, or a pharmaceutically acceptable salt thereof; b) microcrystalline cellulose; and c) starch. 12. The pharmaceutical composition of claim 11, which further comprises silicon dioxide.